KL

Karen Larochelle

Venture Partner and Board Director

Princeton, New Jersey

Overview 

Karen LaRochelle is a highly accomplished Company Strategist and Collaborations Lead, currently serving as a Venture Partner and Board Director. With a background in the pharmaceutical industry, she has excelled in roles such as SVP of Corporate and Business Development at WindMIL Therapeutics and Chief Business Officer at Psioxus Therapeutics. Notable highlights of her career include leading global business development efforts at Bristol-Myers Squibb and serving as a Board Member at PaxMedica, showcasing her expertise in strategic planning, business development, and leadership within the biotechnology sector.

Work Experience 

P

PaxMedica

  • Board Member

    2020 - Current

    Audit and Compensation Committee member

PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

Raised $30,680,000.00 from The Lind Partners.

paxmedica.com

LaRochelle Advisors

  • Consulting Chief Business Officer to multiple biotechs

    2013

    Fractional consulting CBO focused on strategy, Business Development and financing.

AL

Advent Life Sciences LLP

  • Operational Partner

    2020 - 2023

WT

WindMIL Therapeutics

  • SVP, Corporate and Business Development

    2020 - 2021

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.

Raised $42,500,000.00 from Medivate Partners, Camden Partners, Domain Associates, Qiming Venture Partners and FoxKiser.

windmiltx.com
PT

Psioxus Therapeutics

  • Chief Business Officer

    2016 - 2019

LaRochelle Advisors, LLC

  • Biotech Business Development

    2013 - 2016

    Collaboration consultant for biotechnology companies in the US and China. Business Development services to clients interested in out-licensing, strategic collaborations, M&A and in-licensing. Services include partnering strategy, search and evaluation, term sheet development and agreement negotiation. Transactions executed for Exelixis, Ovid Therapeutics, Chase Pharmaceuticals, Otsuka and Yabao Pharmaceuticals

BS

Bristol-Myers Squibb

  • Global Business Development & Head of China Business Development

    1993 - 2013

    Executive Director, Business Development 2006-2013 Head of China Business Development 2010-2013 Director, Business Development 2000-2006 Associate Director, International Finance 1999-2000 Manager, Business Analysis 1995-1999 Financial Associate (MBA rotational program) 1993-1995

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.

bms.com

Anderson Consulting

  • Consultant

    1988 - 1991

Education 

Articles About Karen

Relevant Websites